AtriCure, Inc. engages in the provision of innovative products, professional education, and support for the treatment of atrial fibrillation. Its product, Isolator Synergy Ablation System, is a surgical device that treats the persistent longstanding persistent forms of atrial fibrillation in patients undergoing certain open concomitant procedures. Its cryoICE cryosurgery product offers a variety of cryoablation devices for use in multiple different types of cardiothoracic surgery. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart&#x27;s left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
